The possibility to affect the size, structure, composition, and stability of solid-state particles for drug applications through the preparation of metastable solid-phases from the vapor phase at low temperatures is discussed in the context of drug delivery systems. Some of the important conditions for the cryogenic modification of the solid-state are determined. Examples involving two important drugs are presented, which led to the formation new polymorphs that could be used to create new drug formulations.